Compare Noble Corporation plc (NE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs GeneDx Holdings Corp — how do they compare? Noble Corporation plc trades at $42.5 (market cap $6.73B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Noble Corporation plc is far larger — about 3.3× GeneDx Holdings Corp's market cap, and Noble Corporation plc pays a 4.74% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and GeneDx Holdings Corp for 19 Days on average.
| NE | WGS | |
|---|---|---|
Market Cap | $6.73B | $2.02B |
Volume | 1,027,635 | 734,640 |
Sector | Energy | Health |
52-Week High | $54.37 | $167.51 |
52-Week Low | $26.70 | $34.51 |
Typical Hold Time | 26 Days | 19 Days |
Enterprise Value | $8.16B | $2.05B |
Dividend Yield | 4.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.56, up 3.88% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with a 4.88% net income margin, though recent quarterly earnings have been inconsistent with two misses and one beat. Analyst sentiment is divided with a $52 consensus price target representing 22% upside potential, but ongoing legal investigations create uncertainty.
The stock presents a moderate opportunity with significant analyst upside potential, supported by recent contract wins including the long-term Ghana drilling agreement. However, risks include inconsistent earnings performance, declining profitability margins from 2025 to 2026, and multiple ongoing legal investigations that could impact investor confidence and stock performance in the near term.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
